|
|
Epivir (3TC, Lamivudine)
| Brand Name: |
Epivir |
| Generic Name: |
Lamivudine, 3TC |
| Adult Single Dose: |
One 150-mg tablet (twice a day) OR one 300-mg tablet (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Epivir (3TC, Lamivudine) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Lamivudine (Epivir) (August 22, 2009)
To read PDF, click here
From AIDS InfoNet
- Epivir (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Epivir (Lamivudine, 3TC) (September 28, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Patient Information About Epivir (3TC, Lamivudine) (PDF) (February 2008)
From GlaxoSmithKline
- 3TC (Epivir, Lamivudine) (October 26, 2006)
From AIDS Treatment Data Network
- Epivir (Lamivudine) (September 6, 2006)
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Lamivudine (August 2004)
[Archived Article]
From Project Inform
- Profiles on New Drugs (March 1996)
[Archived Article]
In Moore News for Care Providers, from Johns Hopkins AIDS Service
News
- Epivir Tablets for Pediatric Dosing (February 7, 2008)
From U.S. Food and Drug Administration
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
- WHO Approves New Generic Lamivudine, Fluconazole Pills (July 14, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- WHO Removes Cipla's Lamivudine, Zidovudine Generics From Approved Drug List (June 16, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- FDA Bits: 3TC, Amprenavir and Nandrolone (September 2002)
[Archived Article]
Once-a-day dosing for 3TC (Epivir) approved; new interaction warnings for amprenavir (Agenerase); nandrolone decanoate returns to the U.S. market.
In HIV Treatment ALERTS!, from The Center for AIDS
- Initial Therapy With d4T or 3TC Appears to Confer Survival Benefit (April 1998)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
- 3TC: Glaxo Wellcome Broadens Patient Assistance (June 7, 1996)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- California: 3TC Now Available Through ADAP (May 3, 1996)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- San Francisco: 3TC Available Now to Residents Through ADAP Program (April 5, 1996)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Approvals for 3TC, Saquinavir (December 1995)
[Archived Article]
In TAGline, from Treatment Action Group
- Lamivudine Approved for Combination Use with AZT (December 1, 1995)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- 3TC: Now Available Again Up to CD4 of 300 (August 4, 1995)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
Research
- Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
- Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Once-Daily Abacavir + Lamivudine + Tenofovir Fails in Naive Patients (April 2005)
[Archived Article]
In Expert Opinion on Investigational Drugs, from The Body PRO
- Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- No Difference Seen in Resistance Profiles of Emtricitabine and Lamivudine (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
[Archived Article]
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
[Archived Article]
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from The Body PRO
- Virologic Failure Analyzed in a Trial of Once-Daily Versus Twice-Daily Abacavir/3TC Regimens (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
- Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- FTC Compares Well to 3TC in Triple-NRTI Regimens (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- FTC Similar in Most Ways to 3TC (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
[Archived Article]
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration
- Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
[Archived Article]
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
[Archived Article]
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Separated at Birth: 3TC and FTC (July 2003)
[Archived Article]
A quick comparison of molecular structures.
In TAGline, from Treatment Action Group
- Tenofovir Disoproxil Fumarate and Lamivudine Combination Therapy Compared to Lamivudine Alone for HBV in Therapy-Naive HIV/HBV Co-Infected Patients: 48-Week Interim Results (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Thai Hospital Claims Reduced Mother-Baby Transmission (July 30, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy: 48-Week Interim Results (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Anti-Hepatitis B Virus Activity of Tenofovir Disoproxil Fumarate in Lamivudine Experienced HIV/HBV Co-Infected Patients (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- High Incidence of Primary NNRTI Mutations and M184V in Isolates From Therapy-Experienced Adults Entering the ZORRO Trial (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Breastfeeding Wrecks Short Course Anti-HIV Treatment for Babies (April 10, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Comparative Results (Phase II 48-Week): BMS-232632, Stavudine, Lamivudine as HAART for Treatment-Naive HIV-Positive Patients (AI424-008) (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- HBV: Lamivudine -- When to Start, When to Stop (October 23, 2001)
[Archived Article]
In 66th Annual Scientific Meeting of the American College of Gastroenterology, from The Body PRO
- Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy (July 23, 2001)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Abacavir, Lamivudine and Amprenavir +/- Ritonavir Is a Potent and Well-Tolerated HAART Regimen in Therapy-Naive Subjects (Preliminary Results from GW Protocols) (COL30325) (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice-Daily and Once-Daily Dosing in HIV-1 Infected Individuals (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Efficacy and Safety of Switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Evaluation of Novel Combination of Abacavir, Lamivudine and Efavirenz (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Once-a-Day Therapy for HIV Infection (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Characterization of Lamivudine Pharmacokinetics in Cerebrospinal Fluid and Plasma by Ultra-Intensive Sampling (November 19, 1999)
[Archived Article]
In The 37th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Efavirenz + Zidovudine + Lamivudine Provides Superior Long-Term HIV-RNA Suppression, Antiretroviral Activity and Tolerability Versus Indinavir + ZDV + 3TC: Results of Study 006 at 72 Weeks (Initial Cohort) (November 19, 1999)
[Archived Article]
In The 37th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- A Study in HIV Positive Women of Quadruple Therapy: Nelfinavir, Saquinavir, Stavudine, and Lamivudine (February 4, 1998)
[Archived Article]
From Seattle Treatment Education Project
- Therapy with d4T plus 3TC Produces Sustained Undetectable Levels of Plasma HIV RNA in Patients Treated with Reverse Transcriptase Inhibitors for 10 Years (February 4, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm3 (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- d4T+3TC Versus AZT+3TC: Shattering the Synergy Story (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The START Trials (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- d4T and 3TC Combination Studies Confirm the Effect of the Combination (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Final Results of CAESAR Study Demonstrate a Survival Benefit with 3TC (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- ICAAC Update: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (Winter 1996/1997)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project
- 3TC Clinical Benefit: More Data Presented (October 4, 1996)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
|
Advertisement
|
E-Mail
Glossary
Share